Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Uncovering the molecular mechanism underlying lysine-specific demethylase 6A in Kabuki Syndrome
FY 2020-21
Summary
Kabuki Syndrome is a rare genetic disease that affects 1 in 32,000 individuals and is characterized by intellectual disability, abnormal development of the brain and heart, and malformations of the face and skull. Genetic diseases involve errors in patients' DNA and in Kabuki Syndrome, these errors can occur in a specific DNA segment that codes for the KDM6A protein. This protein modifies complexes around which DNA is wrapped, called histones. By modifying histones, KDM6A can signal to the cell to turn on the production of certain proteins. My preliminary data in stem cell models show that when KDM6A is lost, genes involved in making the cell's respiratory organelle, the mitochondria, are reduced. This proposed research thus aims to understand the molecular mechanism that involves KDM6A, KDM6A-associated histone modifications, and mitochondria biogenesis. Our goal is to understand why the loss of KDM6A causes Kabuki Syndrome. We will be using genetically engineered stem cells and stem cells derived from a patient and the patient's sex-matched parent's blood samples to investigate our question. We expect to see an increase in a specific kind of histone modification mark when KDM6A is lost, which will block mitochondria production and function. By uncovering the molecular mechanism underlying Kabuki Syndrome caused by KDM6A loss-of-function, we hope to help clinicians better understand a subgroup of patients who present with developmental abnormalities, and to open doors to the development of potential treatments for this disorder.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449731
Name
Ni Anjie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering the molecular mechanism underlying lysine-specific demethylase 6A in Kabuki Syndrome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr-Cas9; Disease Modelling; Functional Genetics; Gene Expression; Histone Methylation; Human Induced Pluripotent Stem Cells; Kabuki Syndrome; Mitochondria; Multiple Congenital Anomalies; Rare Disease
Abstract
Kabuki Syndrome is a rare genetic disease that affects 1 in 32,000 individuals and is characterized by intellectual disability, abnormal development of the brain and heart, and malformations of the face and skull. Genetic diseases involve errors in patients' DNA and in Kabuki Syndrome, these errors can occur in a specific DNA segment that codes for the KDM6A protein. This protein modifies complexes around which DNA is wrapped, called histones. By modifying histones, KDM6A can signal to the cell to turn on the production of certain proteins. My preliminary data in stem cell models show that when KDM6A is lost, genes involved in making the cell's respiratory organelle, the mitochondria, are reduced. This proposed research thus aims to understand the molecular mechanism that involves KDM6A, KDM6A-associated histone modifications, and mitochondria biogenesis. Our goal is to understand why the loss of KDM6A causes Kabuki Syndrome. We will be using genetically engineered stem cells and stem cells derived from a patient and the patient's sex-matched parent's blood samples to investigate our question. We expect to see an increase in a specific kind of histone modification mark when KDM6A is lost, which will block mitochondria production and function. By uncovering the molecular mechanism underlying Kabuki Syndrome caused by KDM6A loss-of-function, we hope to help clinicians better understand a subgroup of patients who present with developmental abnormalities, and to open doors to the development of potential treatments for this disorder.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ni, Anjie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~